JFG
KROS icon

Jefferies Financial Group’s Keros Therapeutics KROS Stock Holding History

Jefferies Financial Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-866,737
Closed -$13.7M – 1831
2024
Q4 		$13.7M Hold
866,737
– – 0.08% 179
2024
Q3 		$50.3M Sell
866,737
-32,340
-4% -$1.6M 0.36% 40
2024
Q2 		$41.1M Buy
899,077
+265,406
+42% +$14.3M 0.44% 31
2024
Q1 		$41.9M Buy
633,671
+617,771
+3,885% +$36.6M 0.39% 35
2023
Q4 		$632K Buy
+15,900
New +$499K ﹤0.01% 1124

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jefferies Financial Group's KROS Position: Q1 2025 in Review

Jefferies Financial Group sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 866,737 shares — an estimated $13.7M sold.

Jefferies Financial Group first reported a position in KROS in Q4 2023 and held it in 5 quarters. The position peaked at $50.3M in Q3 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Jefferies Financial Group reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 866,737 Keros Therapeutics shares in Q1 2025, an estimated $13.7M.
  • Jefferies Financial Group first reported a position in Keros Therapeutics in Q4 2023 and held it in 5 quarters.
  • Jefferies Financial Group's Keros Therapeutics position peaked at $50.3M in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Jefferies Financial Group's 13F filing for Q1 2025, filed 8 May 2025.